HYPAQUE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
HYPAQUE by GE HealthCare is clinical pharmacology retrograde introduction of hypaque-cysto solution provides radiopacity of the contents of the urinary bladder. First approved in 1954.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE is a water-soluble radiographic contrast agent (diatrizoate meglumine) administered via retrograde injection into the urinary bladder for diagnostic imaging. It provides radiopacity of bladder contents and lower urinary tract structures, enabling visualization of cystoureteric reflux and bladder function during micturation studies. The agent is not systemically absorbed from the urinary tract and is excreted unchanged, primarily via the kidneys.
LOE Approaching
This legacy diagnostic agent is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team consolidation and shift toward next-generation imaging modalities.
Mechanism of Action
CLINICAL PHARMACOLOGY Retrograde introduction of HYPAQUE-CYSTO solution provides radiopacity of the contents of the urinary bladder. When used during micturation as a function test, it also opacifies the bladder neck and lower urinary tract. Continuous fluoroscopic and monitoring of urinary bladder…
Worked on HYPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.